Rosenthal Elana S, Karchmer Adolf W, Theisen-Toupal Jesse, Castillo Roger Araujo, Rowley Chris F
Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
Am J Med. 2016 May;129(5):481-5. doi: 10.1016/j.amjmed.2015.09.024. Epub 2015 Nov 18.
Infective endocarditis is a serious infection, often resulting from injection drug use. Inpatient treatment regularly focuses on management of infection without attention to the underlying addiction. We aimed to determine the addiction interventions done in patients hospitalized with injection drug use-associated infective endocarditis.
This is a retrospective review of patients hospitalized with injection drug use-associated infective endocarditis from January, 2004 through August, 2014 at a large academic tertiary care center in Boston, Massachusetts. For the initial and subsequent admissions, data were collected regarding addiction interventions, including consultation by social work, addiction clinical nurse and psychiatry, documentation of addiction in the discharge summary plan, plan for medication-assisted treatment and naloxone provision.
There were 102 patients admitted with injection drug use-associated infective endocarditis, 50 patients (49.0%) were readmitted and 28 (27.5%) patients had ongoing injection drug use at readmission. At initial admission, 86.4% of patients had social work consultation, 23.7% had addiction consultation, and 24.0% had psychiatry consultation. Addiction was mentioned in 55.9% of discharge summary plans, 7.8% of patients had a plan for medication-assisted treatment, and naloxone was never prescribed. Of 102 patients, 26 (25.5%) are deceased. The median age at death was 40.9 years (interquartile range 28.7-48.7).
We found that patients hospitalized with injection drug use-associated infective endocarditis had high rates of readmission, recurrent infective endocarditis and death. Despite this, addiction interventions were suboptimal. Improved addiction interventions are imperative in the treatment of injection drug use-associated infective endocarditis.
感染性心内膜炎是一种严重感染,常因注射吸毒所致。住院治疗通常侧重于感染管理,而未关注潜在的成瘾问题。我们旨在确定对因注射吸毒相关感染性心内膜炎住院患者采取的成瘾干预措施。
这是一项对2004年1月至2014年8月在马萨诸塞州波士顿一家大型学术三级医疗中心因注射吸毒相关感染性心内膜炎住院患者的回顾性研究。对于初次及后续入院患者,收集了关于成瘾干预措施的数据,包括社会工作、成瘾临床护士和精神科的会诊情况、出院总结计划中对成瘾情况的记录、药物辅助治疗计划以及纳洛酮的提供情况。
共有102例因注射吸毒相关感染性心内膜炎入院患者,50例(49.0%)再次入院,28例(27.5%)再次入院时仍在注射吸毒。初次入院时,86.4%的患者接受了社会工作会诊,23.7%接受了成瘾会诊,24.0%接受了精神科会诊。55.9%的出院总结计划中提及了成瘾情况,7.8%的患者有药物辅助治疗计划,且从未开具过纳洛酮。102例患者中,26例(25.5%)死亡。死亡患者的中位年龄为40.9岁(四分位间距28.7 - 48.7)。
我们发现,因注射吸毒相关感染性心内膜炎住院患者的再入院率、复发性感染性心内膜炎发生率和死亡率均较高。尽管如此,成瘾干预措施仍未达到最佳效果。在治疗注射吸毒相关感染性心内膜炎时,必须改进成瘾干预措施。